Jan Willem B. de Groot

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne, Mustafa Suker, Karin Groothuis et al. · Journal of Clinical Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Surgery +15

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

Medicine, Oncology, Pharmacology +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

Medicine, Oncology, Pharmacology +11

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Sander Kelderman, Bianca Heemskerk, Harm van Tinteren et al. · Cancer Immunology Immunotherapy · 2014 · 300 citations · Full text

Medicine, Cancer Biology, Oncology +15

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma

Reinhard Dummer, Keith T. Flaherty, Caroline Robert et al. · Journal of Clinical Oncology · 2022 · 185 citations · Full text

Medicine, Oncology, Pharmacotherapy +15